Bit­ter­root Bio nabs $145M Se­ries A with a plan to tack­le chal­leng­ing can­cer tar­get for heart med­i­cines

The founders of can­cer biotech Forty Sev­en had ini­tial­ly en­vi­sioned that the com­pa­ny would al­so work on de­vel­op­ing heart drugs that cut down in­flam­ma­tion. Be­fore …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER